Correlation between fluorodeoxyglucose hotspots on preradiotherapy PET/CT and areas of cancer local relapse: Systematic review of literature |
| |
| Institution: | 1. Service de médecine nucléaire, CHU de Brest, 2, avenue Foch, 29200 Brest, France;2. EA3878 Getbo, IFR 148, Université européenne de Bretagne, boulevard Tanguy-Prigent, 29200 Brest, France;3. Ahmanson Translational Theranostics Division, Department of Medical and Molecular Pharmacology, David-Geffen School of Medicine, University of California, 10833, Le Conte Ave, Los Angeles, CA 90095, United States;4. Service de radiothérapie, CHU de Brest, 2, avenue Foch, 29200 Brest, France;5. Service d’otorhinolaryngologie, CHU de Brest, 2, avenue Foch, 29200 Brest, France;6. Service de médecine nucléaire, centre Henri-Becquerel, 1, rue d’Amiens, 76038 Rouen, France;7. Équipe Quantification en imagerie fonctionnelle (QuantIF), Laboratoire d’informatique, de traitement de l’information et des systèmes (Litis) équipe d’accueil (EA) 4108, CHU de Rouen, 1, rue d’Amiens, 76000 Rouen, France;8. CNRS, Fédération de recherche (FR) 3638, 1, rue d’Amiens, 76000 Rouen, France;1. Department of Radiation Oncology, Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina;2. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey;3. Duke Cancer Institute-Biostatistics, Duke University School of Medicine, Durham, North Carolina;4. Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina;6. Department of Radiology, Duke University School of Medicine, Durham, North Carolina;5. Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, North Carolina;1. Radiology Department, GHU de Paris, centre hospitalier Sainte-Anne, 1, rue Cabanis, 75014 Paris, France;2. Université de Paris, 85, boulevard Saint-Germain, 75006 Paris, France;3. Imabrain, Institut de psychiatrie et neurosciences de Paris (IPNP), 102–108, rue de la Santé, 75014 Paris, France;4. Inserm, U1266, 102, rue de la Santé, 75013 Paris, France;5. Medical Physics Department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France;6. Molecular Radiotherapy, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France;7. Inserm, 114, rue Édouard-Vaillant, 94805 Villejuif, France;8. Paris-Sud University, Paris-Saclay University, 114, rue Édouard-Vaillant, 94805 Villejuif, France;9. Neurosurgery Department, GHU de Paris, centre hospitalier Sainte-Anne, 1, rue Cabanis, 75014 Paris, France;10. Radiotherapy Department, Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France;1. Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany;2. Heidelberg Institute of Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany;3. National Center for Tumor Diseases (NCT), Heidelberg, Germany;4. Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany;5. Department of Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany;6. Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, 69120 Heidelberg, Germany;7. German Cancer Consortium (DKTK), Heidelberg, Germany;8. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany;9. Department of Oral and Maxillofacial Surgery, Heidelberg University Hospital, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany;10. Department of Otorhinolaryngology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany;1. Service d’oncologie radiothérapie, hôpital Haut-Lévêque, centre hospitalier universitaire de Bordeaux, avenue Magellan, 33600 Pessac, France;2. EA 4574 « Sciences, philosophie, humanités », université de Bordeaux–université Bordeaux-Montaigne, domaine universitaire, 33607 Pessac, France;3. Service de pharmacologie médicale, comité de protection des personnes Sud-Ouest et outre-mer III, hôpital Pellegrin, centre hospitalier universitaire de Bordeaux, 33076 Bordeaux, France;4. Faculté de pharmacie, université de Bordeaux, 146, rue Léo-Saignat, 33076 Bordeaux, France;5. Centre de coordination de cancérologie, hôpital Saint-André, centre hospitalier universitaire de Bordeaux, 1, rue Jean-Burguet, 33000 Bordeaux, France;6. Unité de recherche en soins et en sciences humaines, hôpital Pellegrin, centre hospitalier universitaire de Bordeaux, 33076 Bordeaux, France;1. Department of radiation oncology, centre François-Baclesse, 3, avenue General-Harris, 14000 Caen, France;2. Association Advance Resource Centre for Hadrontherapy in Europe (ARCHADE), 3, avenue General-Harris, 14000 Caen, France;3. Laboratoire de physique corpusculaire, Institut national de physique nucléaire et de physique des particules (IN2P3), 6, boulevard Maréchal-Juin, 14000 Caen, France;4. École nationale supérieure d’ingénieurs de Caen (ENSICaen), 6, boulevard Maréchal-Juin, CS 45053, 14050 Caen cedex 4, France;5. Centre national de la recherche scientifique (CNRS), UMR 6534, 6, boulevard Maréchal-Juin, 14000 Caen, France;6. Université de Caen Normandie (Unicaen), esplanade de la Paix, CS 14032, 14032 Caen cedex, France;7. Normandie Université, esplanade de la Paix, CS 14032, 14032 Caen cedex, France;8. Department of radiation oncology, centre Antoine-Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France;9. Department of radiation oncology, institut Curie/Orsay, 25, rue d’Ulm, 75005 Paris, France;10. Department of radiotherapy, groupe hospitalier Pitié-Salpêtrière, Assistance publique-hôpitaux de Paris, 47-83, boulevard de l’Hôpital, 75013 Paris, France;11. Laboratoire de physique subatomique et de cosmologie, IN2P3, 53, avenue des Martyrs, 38000 Grenoble, France;12. Université Grenoble-Alpes, 53, avenue des Martyrs, 38000 Grenoble, France;13. CNRS, UMR 5821, 53, avenue des Martyrs, 38026 Grenoble cedex, France;14. Department of radiotherapy, centre Paul-Strauss, Unicancer, 3, rue de la Porte-de-l’Hôpital, 67065 Strasbourg cedex, France;15. Commissariat à l’énergie atomique (CEA), boulevard Henri-Becquerel, 14000 Caen, France;p. CNRS, UMR 6030 ISTCT, Equipe CERVOxy, boulevard Henri-Becquerel, 14000 Caen, France;q. CervOxy group, groupement d’intérêt public Cyceron, boulevard Henri-Becquerel, 14000 Caen, France |
| |
| Abstract: | The aim of the present paper is to systematically review all available literature on preradiotherapy high uptake areas (hotspots) as a potential target for dose escalation in different tumour sites, and to understand the potential role and limitations of fluorodeoxyglucose (FDG)-positron-emission tomography (PET)/computed tomography (CT) in this context. An electronic database (Medline) search was conducted to identify articles reporting on a correlation between high tracer uptake on pretreatment PET and preferential sites of local recurrence after radiotherapy. Search was limited to English language. No date range limitation was applied. Among 45 studies initially identified, nine series matching with inclusion criteria have finally been retained from the literature after reviewing (5 retrospective and 4 prospective). Primary tumour locations were head-neck (n = 2), lung (n = 4), oesophageal (n = 2) and rectal (n = 1) areas. Overlaps between FDG hotspot on preradiotherapy PET/CT and site of local recurrence on post-treatment scan showed good to excellent agreement. Only studies on head-neck cancer reported moderate agreement probably explained by the lack of reproducibility of the patients positioning between pre- and post-treatment FDG-PET/CT; and by the rigid registration process of images limited by post-therapeutic changes that highly affect anatomical landmarks. FDG hotspot-guided radiotherapy may allow dose escalation in respecting a robust methodology (treatment position, co-registration method, four-dimensional PET). |
| |
| Keywords: | PET/CT FDG hotspots Radiotherapy Local relapse Literature review TEP-TDM FDG « hotspots » Radiothérapie Rechute locale Revue de littérature |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
